{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:12:22Z","timestamp":1790802742226,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Inflammatory bowel diseases (IBDs) are treated with anti-TNF agents. Strategies to monitor response to therapy may improve clinical control of the disease and reduce economical costs. Previous evidence suggests cleavage of infliximab (IFX) by Matrix Metalloproteinase 3 (MMP3) as a mechanism leading to loss of response. Our study aimed to evaluate if MMP3 serum levels could be considered an early marker of anti-TNF nonresponse and to analyze the correlation with other biochemical markers of treatment failure such as IFX trough levels and anti-IFX antibodies, inflammatory markers, and albumin levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospectively, 73 IBD patients who had received IFX for at least 1 year were enrolled: 35 patients were responders and 38 were nonresponders at 52 weeks. Clinical and biochemical data (Harvey-Bradshaw index [HBI], Mayo score, body mass index [BMI], C-reactive protein [CRP], fecal calprotectin and albumin levels), MMP3 serum levels, and drug monitoring were assessed at baseline, postinduction, and 52 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The MMP3 levels were similar at baseline (19.83 vs 17.92 ng\/mL), but at postinduction, patients who failed to respond at 1 year had significantly higher levels than patients who responded (26.09 vs 8.68 ng\/mL, P &amp;lt; 0.001); the difference was confirmed at week 52 (29.56 vs 11.48 ng\/mL, P &amp;lt; 0.001). The MMP3 levels tended to be higher in patients without antidrug antibodies than in patients with antidrug antibodies at postinduction and 52 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The MMP3 serum determination may represent an early marker of response to infliximab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izz195","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T16:14:43Z","timestamp":1567095283000},"page":"756-763","source":"Crossref","is-referenced-by-count":34,"title":["Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab"],"prefix":"10.1093","volume":"26","author":[{"given":"Brigida","family":"Barberio","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Surgery, Oncological and Gastroenterological Sciences, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"D\u2019Inc\u00e0","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Surgery, Oncological and Gastroenterological Sciences, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Facchin","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Surgery, Oncological and Gastroenterological Sciences, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Dalla Gasperina","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Surgery, Oncological and Gastroenterological Sciences, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric Arsen\u00e8","family":"Fohom Tagne","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Surgery, Oncological and Gastroenterological Sciences, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romilda","family":"Cardin","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Surgery, Oncological and Gastroenterological Sciences, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ghisa","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Surgery, Oncological and Gastroenterological Sciences, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Lorenzon","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Surgery, Oncological and Gastroenterological Sciences, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Marinelli","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Surgery, Oncological and Gastroenterological Sciences, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo Vincenzo","family":"Savarino","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Surgery, Oncological and Gastroenterological Sciences, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Zingone","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Surgery, Oncological and Gastroenterological Sciences, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"2020041111452537100_CIT0001","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/jgh.14563","article-title":"Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study","volume":"34","author":"Burisch","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"key":"2020041111452537100_CIT0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4291\/wjgp.v6.i1.13","article-title":"Laboratory markers in ulcerative colitis: current insights and future advances","volume":"6","author":"Cioffi","year":"2015","journal-title":"World J Gastrointest Pathophysiol."},{"key":"2020041111452537100_CIT0003","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther."},{"key":"2020041111452537100_CIT0004","first-page":"1435","article-title":"Biologic concentration testing in inflammatory bowel disease","volume":"21","author":"Vaughn","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2020041111452537100_CIT0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2014","journal-title":"Inflamma Bowel Dis."},{"key":"2020041111452537100_CIT0006","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/flgastro-2016-100685","article-title":"Use of anti-TNF drug levels to optimise patient management","volume":"7","author":"Papamichael","year":"2016","journal-title":"Frontline Gastroenterol."},{"key":"2020041111452537100_CIT0007","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ecco-jcc\/jjw122","article-title":"Post-induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis","volume":"11","author":"Papamichael","year":"2017","journal-title":"J Crohns Colitis."},{"key":"2020041111452537100_CIT0008","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1097\/MIB.0b013e31829cf401","article-title":"Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease","volume":"19","author":"Harper","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"2020041111452537100_CIT0009","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1124\/jpet.106.103465","article-title":"Role of matrix metalloproteinases in intestinal inflammation","volume":"318","author":"Medina","year":"2006","journal-title":"J Pharmacol Exp Ther."},{"key":"2020041111452537100_CIT0010","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nrd2308","article-title":"Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases","volume":"6","author":"Hu","year":"2007","journal-title":"Nat Rev Drug Discov."},{"key":"2020041111452537100_CIT0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000336995","article-title":"The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases","volume":"30","author":"Lakatos","year":"2012","journal-title":"Dig Dis."},{"key":"2020041111452537100_CIT0012","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.dld.2007.05.010","article-title":"Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn\u2019s disease phenotype","volume":"39","author":"Meijer","year":"2007","journal-title":"Dig Liver Dis."},{"key":"2020041111452537100_CIT0013","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s10620-006-9255-5","article-title":"Increased activity and expression of gelatinases in ischemic colitis","volume":"51","author":"Medina","year":"2006","journal-title":"Dig Dis Sci."},{"key":"2020041111452537100_CIT0014","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther."},{"key":"2020041111452537100_CIT0015","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2015.07.002","article-title":"Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease","volume":"149","author":"Biancheri","year":"2015","journal-title":"Gastroenterology."},{"key":"2020041111452537100_CIT0016","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Casteele","year":"2015","journal-title":"Gastroenterology."},{"key":"2020041111452537100_CIT0017","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/00365521.2010.536254","article-title":"Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn\u2019s disease","volume":"46","author":"Steenholdt","year":"2011","journal-title":"Scand J Gastroenterol."},{"key":"2020041111452537100_CIT0018","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology."},{"key":"2020041111452537100_CIT0019","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/ecco-jcc\/jjy109","article-title":"Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: a systematic review with meta-analysis","volume":"12","author":"Ricciuto","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2020041111452537100_CIT0020","first-page":"1079","article-title":"Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multicentre study","volume":"12","author":"Guidi","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2020041111452537100_CIT0021","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/00365521.2014.987809","article-title":"Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease","volume":"50","author":"Sipponen","year":"2015","journal-title":"Scand J Gastroenterol."},{"key":"2020041111452537100_CIT0022","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/ibd.22863","article-title":"Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF\u03b1 blocking agents","volume":"18","author":"Molander","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2020041111452537100_CIT0023","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.crohns.2011.11.002","article-title":"Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF na\u00efve patients with ulcerative colitis","volume":"6","author":"De Vos","year":"2012","journal-title":"J Crohns Colitis."},{"key":"2020041111452537100_CIT0024","doi-asserted-by":"crossref","first-page":"17864","DOI":"10.1073\/pnas.0904174106","article-title":"Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge","volume":"106","author":"Brezski","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020041111452537100_CIT0025","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4161\/mabs.2.3.11780","article-title":"Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?","volume":"2","author":"Brezski","year":"2010","journal-title":"Mabs."},{"key":"2020041111452537100_CIT0026","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbrc.2011.08.029","article-title":"Protein kinase D1 mediates synergistic MMP-3 expression induced by TNF-\u03b1 and bradykinin in human colonic myofibroblasts","volume":"413","author":"Yoo","year":"2011","journal-title":"Biochem Biophys Res Commun."},{"key":"2020041111452537100_CIT0027","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2006.12.004","article-title":"Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut","volume":"114","author":"Andoh","year":"2007","journal-title":"Pharmacol Ther."},{"key":"2020041111452537100_CIT0028","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00535-007-2091-3","article-title":"Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts","volume":"42","author":"Yagi","year":"2007","journal-title":"J Gastroenterol."},{"key":"2020041111452537100_CIT0029","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/gutjnl-2013-306518","article-title":"Identification of inflammatory mediators in patients with Crohn\u2019s disease unresponsive to anti-TNF\u03b1 therapy","volume":"64","author":"Leal","year":"2015","journal-title":"Gut."},{"key":"2020041111452537100_CIT0030","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Pharmacol Ther."},{"key":"2020041111452537100_CIT0031","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4161\/mabs.3.6.18119","article-title":"The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge","volume":"3","author":"Brezski","year":"2011","journal-title":"Mabs."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/5\/756\/33035396\/izz195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/5\/756\/33035396\/izz195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T15:45:53Z","timestamp":1586619953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/26\/5\/756\/5556462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,8,29]]},"published-print":{"date-parts":[[2020,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izz195","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2019,8,29]]}}}